Adamas signs with US Navy to make flu treatment
EMERYVILLE, Calif. — Adamas Pharmaceuticals Inc. said Tuesday it signed a deal with the Unites States Navy to conduct laboratory studies on a potential combination treatment for a variety of influenza strains, including swine flu.
Under the deal, the United States Naval Health Research Center will conduct preclinical studies on Adamas’ possible triple combination antiviral. The goal is to treat several strains of the flu with one drug, in combination with other treatments, including Tamiflu.
Data from the experiments will be used to advance the development of Adamas’ therapy as a potential broad-spectrum antiviral therapy for serious infections caused by influenza A viruses.
Financial details of the partnership were not disclosed.